We have studied the morphological, morphometric parameters of the liver of white rats. Against the background of polypharmacy, when using non-steroidal anti-inflammatory drugs, it was revealed in the structure of the liver, which led to various damage to the liver parenchyma. The simultaneous use of non-steroidal anti-inflammatory drugs leads to acute or chronic liver failure in rats. The longer the therapy for chronic diseases, the more pronounced morphological changes (necrosis, fibrosis, and cholestasis).

Liver, Polypharmacy, Non-Steroidal Therapy, Morphology, Morphomrytic Changes

Baykova I.E., Nikitin I.G. (2009) Medicinal liver damage. RMJ (Russian Medical Journal), 1. pp. 4-10.

Bueverov A.O. (2009) Possibilities of treating drug-induced liver damage in conditions of the need to continue taking hepatotoxic drugs. Treat. physician, 2. Pp. 3-8.

Zvyagintseva T.D., Chernobay A.I. (2011) Medicinal hepatitis: from pathogenesis to treatment. Medicine and Pharmacy News, 375. pp. 23-28.

Zvyagintseva T.D., Chernobay A.I. (2011) Basic principles of treatment of chronic viral hepatitis. In the book: Chronic liver disease. Odessa, pp. 109-153

Zvyagintseva T.D., Chernobay A.I. (2006) Alcohol-viral liver damage: the effectiveness of the new complex hepatoprotector "PM Sirin". Semeina medicine, 2. Pp. 44–48.

Klyuchareva A.A. (2007) Medicinal hepatitis. Medical News, 14. Pp. 19-24.

Morozov Yu.A., Kucheryavyy Yu.A. (2011) Hepatoprotectors in clinical practice: rational aspects of use. A guide for doctors. 4TE Art., Moscow, p. 28.

Polunina T.E. (2013) Management of patients with drug-induced liver damage. Difficult Patient, 4. Pp. 8-13.

Kharchenko N.V., Anokhina G.A., Kharchenko V.V. (2013) Complex multifunctional hepatoprotectors in the treatment of patients with non-alcoholic liver disease in combination with hypertension. Practicing Likar, 1. Pp. 64-66.

Shirokova E.N. (2012) Medicinal lesions of the liver. Lecture at the All-Russian Internet Congress of Specialists in Internal Medicine. (internist.ruhttp: //www.internist.ru/articles/vnutrennie/vnutrennie_671.html).

Shuba N.M., Voronova T.D. (2009) NSAID hepatotoxicity: is there a real threat? Ukr. rheumatol. zhurn., 1 (35). Pp. 33–39.

Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., ... & Daly, A. K. (2011). Case definition and phenotype standardization in drug‐induced liver injury. Clinical Pharmacology & Therapeutics, 89(6), 806-815.

Banks A., Zimmerman H., Isshak K., Harter J.G. (1995) Diclofenak-associated hepatotoxicity: an analysis of 180 cases report to the Food and Drug Administration as adverse reactions. Hepatology. 22 (3). Pp. 820-870.

Bell, L. N., & Chalasani, N. (2009, November). Epidemiology of idiosyncratic drug-induced liver injury. In Seminars in liver disease (Vol. 29, No. 04, pp. 337-347). © Thieme Medical Publishers.

Bhogaraju, A., Nazeer, S., Al-Baghdadi, Y., Rahman, M., Wrestler, F., & Patel, N. (1999). Diclofenac-associated hepatitis. Southern medical journal, 92(7), 711-713.

Leitner, J. M., Graninger, W., & Thalhammer, F. (2010). Hepatotoxicity of antibacterials: pathomechanisms and clinical data. Infection, 38(1), 3-11.

Galati, G., Tafazoli, S., Sabzevari, O., Chan, T. S., & O'Brien, P. J. (2002). Idiosyncratic NSAID drug induced oxidative stress. Chemico-biological interactions, 142(1-2), 25-41.

Hughes, B. (2008). Industry concern over EU hepatotoxicity guidance. Nature Reviews Drug Discovery, 7(9), 719.

Leitner J. M., Graninger W., Thalhammer Infection., 38 (1). pp. 3-11.

Marschall H. U., Wagner M., Zollner G., Trauner M. (2007) Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. Mol. pharm. 4 (6): 895-910.